Liver-Focused chemo after surgery aims to stop cancer return
NCT ID NCT07284394
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether giving chemotherapy directly into the liver artery (HAI) after surgery can prevent cancer from coming back in patients with colorectal cancer that spread to the liver. About 272 high-risk patients will receive either standard IV chemo or HAI chemo plus IV chemo for 3 months. The goal is to see if the targeted approach extends the time before the cancer returns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oxaliplatin
- What this could lead to
- If successful, this approach could significantly lower the chance of liver cancer returning after surgery, improving long-term outcomes for patients at high risk.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. The HAI procedure has higher toxicity, and it may not prove superior to standard IV chemo in preventing recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA METASTATIC IN THE LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can targeted liver chemo turn inoperable tumors into operable ones?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?